DUBLIN--(BUSINESS WIRE)--The "Global Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2012-2018 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.
The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.
Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.
The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2012-2018 includes:
- Trends in asset purchase dealmaking in the biopharma industry since 2012
- Analysis of asset purchase deal structure
- Case studies of real-life asset purchase deals
- Access to over 1,000 asset purchase deal records
- The leading asset purchase deals by value since 2012
- Most active asset purchase dealmakers since 2012
- The leading asset purchase partnering resources
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Asset Purchase dealmaking
Chapter 3 - Overview of Asset Purchase deal structure
Chapter 4 - Leading Asset Purchase deals
Chapter 5 - Top 50 most active Asset Purchase dealmakers
Chapter 6 - Asset Purchase deals including contracts directory
Appendix 1 - Asset Purchase dealmaking by companies A-Z
Appendix 2 - Asset Purchase dealmaking by industry sector
Appendix 3 - Asset Purchase dealmaking by stage of development
Appendix 4 - Asset Purchase dealmaking by therapy area
Appendix 5 - Asset Purchase dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/research/jsrcmq/global_pharma?w=4